Menarini Group Unveils New ELZONRIS® Data at Hematology Meeting

The Menarini Group is set to present new data on ELZONRIS® (tagraxofusp-erzs) at the upcoming American Society of Hematology Annual Meeting. The drug shows promise for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic malignancy. Comprising five abstracts, including two oral presentations, the data highlights the efficacy and tolerability of a combination therapy involving tagraxofusp, azacitidine, and venetoclax.

ELZONRIS®, approved by the FDA in 2018, targets BPDCN—a cancer affecting skin, bone marrow, and blood. BPDCN is characterized by an overexpression of the CD123 protein, making it a target for precision therapies. The Menarini Group aims to transform cancer treatment through such innovative approaches.